Brawn Biotech Limited, formerly known as **Brawn Pharmaceuticals Ltd.**, is a **fully integrated healthcare group** with a legacy spanning nearly **40 years**. Since its incorporation in **1985**, the company has evolved into a specialized player in the Indian pharmaceutical landscape, maintaining a lean and centralized organizational structure. The company operates as a **single-segment entity** focused exclusively on **Pharmaceuticals**, in accordance with **Ind-AS 108**. This focused approach allows for concentrated resource allocation and streamlined management oversight. | Feature | Details | | :--- | :--- | | **Corporate Identity Number (CIN)** | **L74899DL1985PLC022468** | | **Listing Status** | Publicly listed on the **Bombay Stock Exchange (BSE)** | | **Registered Office** | C-64, Lajpat Nagar-1, **New Delhi-110024** | | **Manufacturing Facility (Works)** | Plot No. 44, Pace City-1, Sector 37, **Gurugram-122001, Haryana** | | **Corporate Office** | Plot No. 30, Sector 33, Near Hero Honda Factory, **Gurugram-122001** | | **Subsidiaries/JVs** | **None** (Operates as a standalone entity) | --- ### **Therapeutic Depth & Product Portfolio** Brawn Biotech maintains a diversified pharmaceutical portfolio covering **12 major segments**. The company manages the entire product lifecycle from development to market presence, ensuring a balanced revenue stream between essential acute treatments and long-term chronic therapies. #### **Core Therapeutic Categories** * **Chronic Care Management:** A high-growth focus area including **Cardiovasculars**, **Antidiabetics**, **Antipsychotics**, **Antiasthmatics**, and **Respiratory solutions**. * **Acute Care & Anti-Infectives:** A robust range of **Antibacterials**, **Antifungals**, and **Antimalarials**. * **Consumer & General Health:** High-volume products including **Analgesics**, **Gastrointestinals**, **Antacids**, and **Nutritionals**. * **Specialty Care:** Targeted solutions for **Skin Care** and dermatology. --- ### **Strategic Growth Pillars & Market Outlook** The company’s strategy is designed to capitalize on India’s status as a global pharmaceutical hub. Management is focused on transitioning from a traditional manufacturer to a high-value partner in the global supply chain by leveraging **innovation** and **cost-effective manufacturing**. #### **Key Strategic Objectives** * **Domestic Market Penetration:** Accelerating sales by capturing the rising demand for **generic medicines** and expanding the **chronic therapy** footprint. * **Rural Market Expansion:** Implementing targeted strategies to penetrate **rural demographics**, tapping into underserved populations with increasing healthcare awareness. * **Global Positioning:** Positioning the company as a preferred manufacturing partner for **developed markets** seeking high-quality, cost-effective alternatives. * **Value Chain Progression:** Investing in **Biotechnology** and **R&D** to move beyond basic formulations into more complex **drug discovery** and innovative solutions. | Growth Driver | Strategic Focus | | :--- | :--- | | **Customer Acquisition** | Expanding the client base through both existing portfolios and new product launches. | | **Operational Agility** | Balancing **short-term market opportunities** with **long-term strategic partnerships**. | | **Economic Tailwinds** | Leveraging **policy reforms** and improved **investor confidence** in the Indian economy. | --- ### **Governance, Internal Controls & Compliance** Brawn Biotech adheres to rigorous governance standards to ensure financial integrity and operational transparency. The company’s internal control systems are designed to be commensurate with the **size and complexity** of its business operations. * **Financial Reporting:** All financial results are prepared in strict compliance with **Section 133 of the Companies Act, 2013** and **Indian Accounting Standards (Ind AS)**. * **Independent Audit:** Internal audits are conducted by **M/s Sahil Pasricha & Associates**, who perform independent evaluations of internal controls and concurrent audits of financial transactions. * **Fraud Prevention:** The Board maintains active policies for the **prevention and detection of frauds and errors**, ensuring high levels of accountability. --- ### **Risk Management & Mitigation Framework** Operating in a highly regulated global industry, Brawn Biotech faces a complex array of macroeconomic and sector-specific challenges. The company proactively monitors these risks to ensure long-term stability. #### **Primary Risk Factors** * **Regulatory & Quality Compliance:** Navigating increasingly **stringent global regulatory frameworks** and quality audits. Any shift in domestic or international compliance standards requires immediate operational adaptation. * **Market Dynamics:** Facing intense **pricing pressures** and margin erosion in the **complex generics** segment due to heightened competition. * **Macro-Financial Volatility:** Exposure to **currency fluctuations (FX risk)** and **geopolitical uncertainties** that impact international trade and supply chain costs. * **Digital Resilience:** Addressing the rise of **cybersecurity threats** and data breaches as the company undergoes **digital transformation**. * **Sustainability Mandates:** Meeting evolving **Environmental, Social, and Governance (ESG)** norms, which require continuous investment in sustainable manufacturing practices. | Risk Category | Focus Area for Mitigation | | :--- | :--- | | **Regulatory** | Continuous quality audits and adherence to evolving international frameworks. | | **Financial** | Hedging against **FX volatility** and optimizing cost structures to counter pricing erosion. | | **Operational** | Strengthening **data security** and digital infrastructure resilience. | | **ESG** | Aligning corporate responsibility with global **environmental sustainability** standards. |